Skip to content

JUMP_START - Optimization of Care for Young Cancer Patients with Gastrointestinal Tumors

JUMP_START - Optimization of Care for Young Cancer Patients with Gastrointestinal Tumors

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06621277
Acronym
JUMP_START
Enrollment
250
Registered
2024-10-01
Start date
2023-10-01
Completion date
2030-12-31
Last updated
2024-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal Cancer

Keywords

Quality of Life, gastrointestinal tumors

Brief summary

JUMP\_START aims to assess the needs of individuals aged ≤ 50 years with gastrointestinal (GI) tumors and implement a tailored support and counseling program at the University Hospital Heidelberg and the National Center for Tumor Diseases (NCT). In phase 1A, 12-15 individuals aged ≤ 50 years with GI tumors will be interviewed via telephone using semi-structured interviews to obstain a detailed understanding of the life situation, the burdens, and the care situation within the structures of the NCT Heidelberg. In phase 1B, the care networks of young patients with GI tumors beyond the NCT, including the analysis of changes and important access routes/possible gatekeepers, will be explored using so-called ego-centered network analyses, in comparison with patients who received a GI tumor diagnosis after the age of 50. In response to the results of phase 1A and 1B, the care services for young patients with GI tumors will be optimized, and tailored counseling programs will be developed in phase 2. These project phases will be accompanied by Quality of Life assessments using European Organisation for Research and Treatment of Cancer (EORTC) questionnaires. All patients with GI tumors (regardless of potential inclusion in phase 1A or 1B) will receive the EORTC questionnaires once. In phase 2, Quality of Life will be assessed every 6 months.

Interventions

OTHERNo intervention

No intervention

OTHERTailored counseling programs (Phase 2)

Optimized care services and tailored counseling programs for young patients with GI tumors at the Heidelberg University Hospital (Phase 2)

Sponsors

University Hospital Heidelberg
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Individuals aged ≥ 18 and ≤ 50 years receiving treatment for a GI tumor at the Heidelberg University Hospital * Sufficient knowledge of the German language * Capable of providing informed consent * Additional recruitment for Phase 1B and Quality of Life assessments: Patients with GI tumor aged ≥ 51 years

Exclusion criteria

* Individuals with a GI tumor diagnosis after the age of 50 (except in Phase 1B and for Quality of Life assessments) * Individuals with a GI tumor diagnosis under the age of 18 * Lack of capacity to consent and/or absence of informed consent * Insufficient knowledge of the German language * Severe cognitive impairments

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline in Quality of Life at two yearsBaseline, 6; 12; 18, and 24 monthsChanges in Quality of Life in patients aged ≤ 50 years with a GI tumor diagnosis who are using optimized counseling programs will be measured using EORTC questionnaires (e.g. EORTC-QLQ C30, EORTC QLQ-CR29, EORTC LMC21, EORTC HCC18, EORTC QLQ-OG25). Scores will be categorized into functional and symptom scales (0-100 range) following the EORTC Scoring Manual. For Functional scales and Global QoL: Higher scores indicate better functioning or better QoL. For Symptom scales: Higher scores indicate greater symptom burden.

Other

MeasureTime frameDescription
Differences in Quality of Life between patients aged ≤ 50 years and > 50 yearsOnce at baseline, after enrollmentDifferences in Quality of Life in patients aged ≤ 50 years and \> 50 years with a GI tumor diagnosis will be measured using EORTC questionnaires (e.g. EORTC-QLQ C30, EORTC QLQ-CR29, EORTC LMC21, EORTC HCC18, EORTC QLQ-OG25). Scores will be categorized into functional and symptom scales (0-100 range) following the EORTC Scoring Manual. For Functional scales and Global QoL: Higher scores indicate better functioning or better QoL. For Symptom scales: Higher scores indicate greater symptom burden.

Countries

Germany

Contacts

Primary ContactBruno C. Köhler
jump-start.nct@med.uni-heidelberg.de+49 6221 5635676

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026